Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,184 recruiting studies in this area right now.
By phase
- Not applicable2,936
- Phase 2755
- Phase 1540
- Phase 3382
- Phase 1/Phase 2297
- Phase 4211
- Phase 2/Phase 363
Top conditions
- Breast Cancer1,226
- Melanoma183
- Rheumatoid Arthritis142
- Metastatic Breast Cancer140
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer93
- Ovarian Cancer92
- Psoriasis88
- Breast Carcinoma83
- Lung Cancer79
- Prostate Cancer70
- Rheumatoid Arthritis (RA)65
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University66
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals47
- Mayo Clinic42
- Assistance Publique - Hôpitaux de Paris41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California421
- Arizona159
- Florida131
- Alabama127
- New York109
- Texas107
- Massachusetts93
- Maryland91
- Pennsylvania75
- North Carolina68
Recruiting studies5,184 total
- NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04504136Recruiting
Study how gut lining heals in inflammatory bowel disease
This study looks at how the lining of the colon heals in people with inflammatory bowel disease (ulcerative colitis or Crohn’s disease). It may help researchers understand whether anti-TNF treatment improves healing, especially when people have limited prior response or are starting biologic therapy.
Lexington, KentuckyAges 18–90 - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Birmingham, AlabamaAges 18 years+ - NCT04513028Recruiting
Beta-glucan with immunotherapy for melanoma immune response
This study tests whether taking beta-glucan alongside pembrolizumab changes how your immune system responds in people with stage III–IV melanoma. It may help researchers understand whether beta-glucan improves immunotherapy activity after cancer has been controlled.
Louisville, KentuckyAges 18 years+ - NCT04520217RecruitingPhase 1
Topical imipramine for skin UVB light sensitivity
This Phase 1 study tests whether a cream called imipramine can reduce tiny UVB-triggered skin “microvesicles” in people who are sensitive to sunlight. The goal is to see if the cream is safe and may lessen harmful skin reactions from UVB exposure.
Fairborn, OhioAges 18–50 - NCT04523857RecruitingPhase 2
Abemaciclib and hydroxychloroquine after breast cancer relapse risk
This Phase 2 trial tests whether abemaciclib plus hydroxychloroquine can kill tiny “leftover” cancer cells in the bone marrow after standard breast cancer treatment. It may help lower the chance of cancer coming back by targeting minimal residual disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT04528355Recruiting
Study of hospital data after stem cell transplant for non-cancer illness
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
Pittsburgh, PennsylvaniaAges 2 months–60 years - NCT04528082RecruitingPhase 3
Apremilast for children with frequent mouth ulcers from Behçet’s disease
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
BronAges 2–17 - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04532047RecruitingPhase 1
Fetal enzyme therapy trial for certain inherited storage disorders
This Phase 1 trial tests an enzyme replacement treatment given to a developing baby before birth for specific inherited “lysosomal storage” diseases. The goal is to see if the treatment is safe and can improve outcomes for babies diagnosed in pregnancy.
San Francisco, CaliforniaAges 18–50 - NCT04530890Recruiting
Testing blood tumor DNA in digestive and breast cancers
This study looks at a blood test for “circulating tumor DNA” (tiny pieces of cancer-related DNA in the blood). It may help doctors learn more about digestive, gynecologic, or breast cancers and how patients respond when treatment like chemotherapy or immunotherapy is needed.
PoitiersAges 18 years+ - NCT04531696Recruiting
Post-death breast tissue donation study for cancer research
This trial invites adults with certain breast cancer conditions to donate tissue after death. Researchers hope the donated samples will help better understand cancer and improve future treatments.
LeuvenAges 18 years+ - NCT04534127Recruiting
DaRT radiation device for skin and mouth or superficial tumors
This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.
JerusalemAges 18 years+ - NCT04533152Recruiting
Study risk factors for healing in diabetic foot ulcers
This study looks at what factors affect outcomes in adults with diabetic foot ulcers. It may help doctors better predict healing and complications by better understanding what influences progress.
CaenAges 18 years+ - NCT04538937Recruiting
Study of high eosinophils causing lung/airway damage
This registry study looks at adults with high eosinophils (a type of immune cell) that are believed to be causing damage in the airways or lungs. It aims to better identify these eosinophils and understand what is going on so future treatments can improve.
InnsbruckAges 18 years+ - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT04553770RecruitingPhase 2
Trastuzumab deruxtecan with or without anastrozole for early breast cancer
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
Fullerton, CaliforniaAges 18 years+ - NCT04560803Recruiting
Skin grafts to help radiation wounds heal faster
This study tests a small skin graft approach to help wounds caused by prior radiation heal better. If you have a radiation-related skin wound that usually heals slowly on its own, this may speed healing and improve comfort.
Boston, MassachusettsAges 18–80 - NCT04562623Recruiting
Studying immune changes in operable breast and ovarian cancers
This study looks at how your immune system behaves around the time of planned surgery for certain breast or ovarian cancers. It may help researchers understand what immune changes happen and how they relate to your cancer.
Lyon, FranceAges 18 years+ - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT04567706Recruiting
Melanoma tissue samples storage for future research
This study is about collecting and storing tissue samples from people affected by melanoma so researchers can use them for future studies. It may help speed up research, but it is mainly about sample storage rather than testing a new treatment.
Columbus, OhioAges Any age - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,184 recruiting dermatology studies from the U.S. registry right now, out of 8,288 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.